Aptose Biosciences Inc. (NASDAQ:APTO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “

Other equities analysts have also recently issued reports about the stock. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $23.00 price target on shares of Aptose Biosciences in a research note on Monday, June 13th. RBC Capital Markets reiterated an “outperform” rating on shares of Aptose Biosciences in a report on Tuesday, September 13th. Finally, Roth Capital upgraded shares of Aptose Biosciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $4.00 to $8.00 in a report on Monday, June 13th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $12.30.

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/aptose-biosciences-inc-apto-upgraded-to-hold-by-zacks-investment-research.html

Aptose Biosciences (NASDAQ:APTO) traded up 5.2168% during midday trading on Tuesday, hitting $2.3779. 29,362 shares of the stock were exchanged. The company’s market cap is $30.66 million. The firm’s 50 day moving average price is $2.18 and its 200 day moving average price is $2.47. Aptose Biosciences has a 12 month low of $1.92 and a 12 month high of $6.40.

An institutional investor recently bought a new position in Aptose Biosciences stock. Bank of Montreal Can purchased a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned approximately 0.43% of Aptose Biosciences as of its most recent filing with the SEC. Hedge funds and other institutional investors own 19.47% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

5 Day Chart for NASDAQ:APTO

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.